4,588 Shares in IQVIA Holdings Inc. $IQV Bought by Evolve Private Wealth LLC

Evolve Private Wealth LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,588 shares of the medical research company’s stock, valued at approximately $886,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. BlackRock Inc. acquired a new stake in IQVIA in the 2nd quarter valued at about $2,811,292,000. Geode Capital Management LLC grew its holdings in IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners increased its position in IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in IQVIA by 16.2% in the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after buying an additional 528,753 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Stifel Nicolaus increased their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. TD Cowen lifted their price objective on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Mizuho upped their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Up 0.1%

IQV opened at $260.17 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $260.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market capitalization of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. The stock has a fifty day moving average of $213.32 and a 200-day moving average of $187.21.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the previous year, the business posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In related news, insider W Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by company insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.